Search

A recent study evaluated the safety outcomes of transitioning obinutuzumab, an anti-CD20 monoclonal antibody, from a standard rate to a short duration infusion (SDI) in patients with chronic lymphocytic leukemia (CLL). Infusion-related reactions (IRRs) are a common adverse event associated with obinutuzumab, and the study aimed to assess the impact of the updated infusion rate on safety outcomes and infusion chair time. The study found that SDI obinutuzumab was safe and well-tolerated, with no incidents of IRRs observed in patients transitioning to the SDI rate. The use of SDI obinutuzumab has the potential to save significant infusion chair time and improve patient convenience and satisfaction. However, the study had limitations, and further research is needed to confirm these findings in a larger cohort of patients with CLL. [Extracted from the article]